1 week Ago By ABMN Staff
Legal & General Group Plc lifted its stake in Rocket Pharmaceuticals, Inc. ( NASDAQ:RCKT – Free Report ) by 3.3% in the 4th quarter, Holdings Channel.
com reports. The institutional investor owned 75,454 shares of the biotechnology company’s stock after acquiring an additional 2,416 shares during the quarter. Legal & General Group Plc’s holdings in Rocket Pharmaceuticals were worth $948,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of the stock. Invesco Ltd. boosted its position in shares of Rocket Pharmaceuticals by 1.
5% in the fourth quarter. Invesco Ltd. now owns 357,840 shares of the biotechnology company’s stock worth $4,498,000 after buying an additional 5,218 shares during the period.
ADAR1 Capital Management LLC boosted its position in shares of Rocket Pharmaceuticals by 4,816.3% in the fourth quarter. ADAR1 Capital Management LLC now owns 211,400 shares of the biotechnology company’s stock worth $2,657,000 after buying an additional 207,100 shares during the period.
Aristides Capital LLC purchased a new stake in shares of Rocket Pharmaceuticals in the fourth quarter worth about $219,000. Envestnet Asset Management Inc. boosted its position in shares of Rocket Pharmaceuticals by 4.
1% in the fourth quarter. Envestnet Asset Management Inc. now owns 32,422 shares of the biotechnology company’s stock worth $408,000 after buying an additional 1,280 shares during the period.
Finally, Wells Fargo & Company MN boosted its position in shares of Rocket Pharmaceuticals by 40.9% in the fourth quarter. Wells Fargo & Company MN now owns 34,970 shares of the biotechnology company’s stock worth $440,000 after buying an additional 10,147 shares during the period.
Hedge funds and other institutional investors own 98.39% of the company’s stock. Wall Street Analysts Forecast Growth RCKT has been the topic of several recent analyst reports.
Needham & Company LLC reiterated a “buy” rating and issued a $42.00 price target on shares of Rocket Pharmaceuticals in a research note on Wednesday, April 9th. Scotiabank boosted their price target on Rocket Pharmaceuticals from $51.
00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Monday, March 3rd. BMO Capital Markets initiated coverage on Rocket Pharmaceuticals in a research note on Wednesday, March 12th.
They issued an “outperform” rating and a $50.00 price target on the stock. Canaccord Genuity Group cut their price target on Rocket Pharmaceuticals from $39.
00 to $36.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. Finally, Chardan Capital cut their price target on Rocket Pharmaceuticals from $62.
00 to $54.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company.
Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.00. Insider Activity In other news, CEO Gaurav Shah purchased 20,000 shares of Rocket Pharmaceuticals stock in a transaction dated Thursday, April 10th.
The stock was bought at an average price of $5.08 per share, with a total value of $101,600.00.
Following the completion of the acquisition, the chief executive officer now owns 792,680 shares in the company, valued at $4,026,814.40. The trade was a 2.
59 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website . Also, CFO Aaron Ondrey sold 7,489 shares of the company’s stock in a transaction dated Friday, April 4th.
The stock was sold at an average price of $5.29, for a total transaction of $39,616.81.
Following the completion of the sale, the chief financial officer now directly owns 129,650 shares of the company’s stock, valued at $685,848.50. The trade was a 5.
46 % decrease in their position. The disclosure for this sale can be found here . Corporate insiders own 28.
50% of the company’s stock. Rocket Pharmaceuticals Stock Performance Rocket Pharmaceuticals stock opened at $7.23 on Monday.
The company has a market cap of $770.93 million, a PE ratio of -2.63 and a beta of 1.
00. The company has a fifty day moving average price of $7.64 and a two-hundred day moving average price of $11.
32. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.
05 and a quick ratio of 6.05. Rocket Pharmaceuticals, Inc.
has a 12 month low of $4.55 and a 12 month high of $26.98.
Rocket Pharmaceuticals ( NASDAQ:RCKT – Get Free Report ) last released its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.
68) by $0.06. Research analysts expect that Rocket Pharmaceuticals, Inc.
will post -2.83 earnings per share for the current year. About Rocket Pharmaceuticals ( Free Report ) Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases.
It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. See Also Want to see what other hedge funds are holding RCKT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rocket Pharmaceuticals, Inc.
( NASDAQ:RCKT – Free Report ). Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
